$LGVN

Longeveron's Chief Medical Officer, Dr. Nataliya Agafonova, will step down effective October 14, 2026, according to an SEC filing. No reason or replacement details were disclosed.

Longeveron Inc. (LGVN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On October 7, 2026, Dr. Nataliya Agafonova informed management of Longeveron Inc. of her decision to step down as Chie

Viking Therapeutics (VKTX) rose 24% in September after positive Phase 1 data for VK2735, a weight-loss drug, but ended the month down 3.18% due to a $575M financing. Longeveron (LGVN) fell 64% after its stem cell therapy failed a Phase 2b trial, triggering a strategic review. The broader biotech sector declined 3.5% in September.

Longeveron Inc. (LGVN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) ------------------- Company Announces Exploration of All Options to Maximize Shareholder Value ● Th

Longeveron Inc. (LGVN) shares fell 60% after its stem cell therapy failed to meet the primary goal in a late-stage trial for a rare pediatric heart condition. The company plans to cut costs and explore strategic alternatives. It had $10.1M in cash at the end of June, with operations funded into Q4. The FDA had previously indicated that the trial's primary endpoint alone would not support approval.

Longeveron Inc. (LGVN) reported that its Phase 2b trial for a heart treatment missed the primary efficacy endpoint. The company is reviewing strategic options, engaging an investment bank, and implementing cash-conservation measures. LGVN had $10.1M in cash as of June 30, with operations expected to be funded into Q4 2026. The company's aging-related frailty program and intellectual property may retain value for potential partners.

Longeveron Inc (LGVN) shares fell 59% after its stem cell therapy failed to meet the main goal in a mid-stage study for a rare infant heart defect. The company now plans to review options to protect shareholders, with $10M in cash to fund operations into Q4. The FDA had previously indicated the study's main measure was inadequate for approval.

Longeveron (LGVN) reported a Q2 2026 net loss of $6.1M, a 22% increase due to higher expenses. Revenue was $0.3M, down 10% YoY. Cash reserves of $10.1M are expected to last until Q4 2026. The company anticipates ELPIS II trial results in September 2026 and is seeking partnerships for its stem cell therapy, laromestrocel. It also received a $1M XPRIZE award and aims for potential $81M grand prize.

Longeveron Inc. (LGVN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Longeveron Appoints Nirav Jhaveri as Chief Financial Officer ● Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Fla., August 19, 2

Longeveron Inc. (LGVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update ● On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrom